Zenas BioPharma (ZBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
16 Mar, 2026Voting matters and shareholder proposals
Election of two Class II director nominees, James Boylan and Patrick Enright, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Provision to transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zenas BioPharma
- Obexelimab nears launch for IgG4-RD, with a robust neuro pipeline advancing toward key milestones.ZBIO
7th Annual HCW Neuro Perspectives Hybrid Conference15 Jun 2026 - Advancing best-in-class therapies for autoimmune diseases with strong late-stage clinical momentum.ZBIO
Corporate presentation3 Jun 2026 - Obexelimab and orelabrutinib advance toward 2027 launches, targeting multi-billion dollar markets.ZBIO
Corporate presentation13 May 2026 - Q1 2026 net loss rose to $81M; positive Phase 3 data and financing extend runway into 2029.ZBIO
Q1 202613 May 2026 - Directors were elected and the auditor ratified, with final results to be filed in Form 8-K.ZBIO
AGM 202611 May 2026 - 2026 meeting to elect directors, ratify auditor, and highlight governance, compensation, and ESG.ZBIO
Proxy Filing16 Mar 2026 - Late-stage pipeline and global launch readiness drive multi-billion dollar autoimmune market entry.ZBIO
Corporate presentation16 Mar 2026 - Strong clinical progress and financing position offset by increased net loss in 2025.ZBIO
Q4 202516 Mar 2026 - Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond.ZBIO
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026